Antitumor activity of Titanocene Y against freshly explanted human breast tumor cells and in xenografted MCF-7 tumors in mice
| Autor: | Volker Schirrmacher, Philipp Beckhove, Nigel J. Sweeney, Matthias Tacke, Katja Strohfeldt, Axel R. Hanauske, Clara Pampillón, Olaf Oberschmidt |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Cancer Research
Antineoplastic Agents Breast Neoplasms Mice chemistry.chemical_compound Organ Culture Techniques Breast cancer Cell Line Tumor Organometallic Compounds medicine Animals Humans Pharmacology (medical) Pharmacology Antitumor activity Cisplatin Cancer medicine.disease Xenograft Model Antitumor Assays Anticancer drug Agar Titanocene Y Oncology chemistry MCF-7 Immunology Cancer research Female Human breast Neoplasm Transplantation medicine.drug |
| Zdroj: | Anti-Cancer Drugs. 18:311-315 |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/cad.0b013e328010a6f7 |
| Popis: | Bis-[(p-methoxybenzyl)cyclopentadienyl] titanium dichloride, better known as Titanocene Y, is a newly synthesized transition metal-based anticancer drug. We studied the antitumor activity of Titanocene Y with concentrations of 2.1, 21 and 210 micromol/l against a freshly explanted human breast cancer, using an in-vitro soft agar cloning system. The sensitivity against Titanocene Y was highly remarkable in the breast cancer tumor in the full concentration range. Titanocene Y showed cell death induction at 2.1 micromol/l, well comparable to cisplatin, given at a concentration of 1.0 micromol/l. A further preclinical development of Titanocene Y was warranted and therefore an MCF-7 human breast cancer xenograft nonobese diabetic/severe combined immunodeficient mouse model was used. Titanocene Y was given for 21 days at 30 mg/kg/day (75% of the maximum tolerable dose of Titanocene Y), which resulted in the reduction of the tumor volume to around one-third, whereas no mouse was lost because of the surprisingly low toxicity of Titanocene Y. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|